Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07615010 | A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure | PHASE2 | RECRUITING | 90 | — | — | May 22, 2026 | Aug 1, 2027 | May 29, 2026 | 4 | United States, Ukraine |
| Arm | Type | Description |
|---|---|---|
| agenT-797 plus SOC | EXPERIMENTAL | Participants will receive agenT-797 and SOC. |
| Placebo plus SOC | PLACEBO_COMPARATOR | Participants will receive placebo and SOC. |
| Name | Type | Description |
|---|---|---|
| agenT-797 | DRUG | Intravenous infusion |
| Placebo | DRUG | Intravenous infusion |
| Standard of Care (SOC) | DRUG | Antimicrobial therapy and corticosteroids per applicable guidelines. |
Key Inclusion Criteria: * Admission to an intensive care unit (ICU) with severe pneumonia of any etiology (viral, bacterial, fungal, or mixed), with and without trauma based on clinical suspicion * Acute hypoxemic respiratory failure (AHRF) * Evidence of moderate to severe acute respiratory distres...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tozorakimab |
| GSK plc Sponsored ADR | GSK | 3 | PHASE1 | Pn-MAPS30plus, PCV20 |
| Pfizer Inc. | PFE | 4 | — | Receipt of PCV20 |
| Sanofi SA Sponsored ADR | SNY | 1 | — | Undisclosed |
| Gilead Sciences, Inc. | GILD | 1 | — | Undisclosed |
| Grace Therapeutics, Inc. | GRCE | 1 | NA | Undisclosed |
| Co-Diagnostics, Inc. | CODX | 1 | — | Undisclosed |